Loading clinical trials...
Loading clinical trials...
Everolimus and Epoetin for Sustained Liver Transplant Tolerance (EVEREST)(ITN101ST)
Conditions
Interventions
Everolimus
Epoetin alfa
Locations
3
United States
University of California San Francisco School of Medicine
San Francisco, California, United States
Northwestern University Feinberg School of Medicine
Chicago, Illinois, United States
University of Pennsylvania Medical Center
Philadelphia, Pennsylvania, United States
Start Date
January 21, 2026
Primary Completion Date
June 1, 2030
Completion Date
June 1, 2030
Last Updated
April 6, 2026
NCT07233096
NCT07315204
NCT06169592
NCT06958796
NCT07291258
NCT06717919
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions